Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials

Alessandro Ottaiano, Monica Capozzi, Chiara De Divitiis, Alfonso De Stefano, Gerardo Botti, Antonio Avallone, Salvatore Tafuto

Research output: Contribution to journalReview article

Abstract

Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results. We performed a meta-analysis in order to quantify the effect size on survival of adding targeted therapy to single agent gemcitabine. Methods: Randomized phase III trials comparing gemcitabine mono-therapy versus gemcitabine plus a targeted agent in first-line treatment of advanced pancreatic cancer designed on survival as primary outcome were selected. Search was done through Medline and the registry of the NIH. Keywords used for searching were ‘pancreas’, ‘pancreatic’, ‘gemcitabine’. Study quality was assessed with MERGE criteria. Findings were depicted in classical Forest plots. Publication bias was evaluated by the construction of funnel plot. Results: Nine studies met the meta-analysis inclusion criteria including 4564 patients. The target therapies were: erlotinib, cetuximab, rigosertib, elpamotide, bevacizumab, aflibercept, axitinib, masitinib and ganitumab. There was no statistically significant heterogeneity among the nine trials (p = 0.77). The hazard ratio (HR) of the pooled analysis was 0.998 (CI 95%: 0.932–1.068). Subgroup meta-analysis was also performed in anti-EGFR and anti-angiogenesis trials: the pooled HR were 0.94 (CI 95%: 0.705–1.175) and 1.055 (CI 95%: 0.913–1.197), respectively. Conclusions: The present meta-analysis does not show significant improvements in survival for targeted drugs in advanced pancreatic cancer. The possible reason of these results could be linked to the biology of pancreatic cancer as well as to the absence of predictive factors.

Original languageEnglish
Pages (from-to)377-383
Number of pages7
JournalActa Oncologica
Volume56
Issue number3
DOIs
Publication statusPublished - Mar 4 2017

Fingerprint

gemcitabine
Pancreatic Neoplasms
Meta-Analysis
Survival
Therapeutics
Publication Bias
Registries
Pancreas

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer : a meta-analysis of randomized phase III trials. / Ottaiano, Alessandro; Capozzi, Monica; De Divitiis, Chiara; De Stefano, Alfonso; Botti, Gerardo; Avallone, Antonio; Tafuto, Salvatore.

In: Acta Oncologica, Vol. 56, No. 3, 04.03.2017, p. 377-383.

Research output: Contribution to journalReview article

@article{dcff7b3db0ca4fde892839d01ac47940,
title = "Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer: a meta-analysis of randomized phase III trials",
abstract = "Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results. We performed a meta-analysis in order to quantify the effect size on survival of adding targeted therapy to single agent gemcitabine. Methods: Randomized phase III trials comparing gemcitabine mono-therapy versus gemcitabine plus a targeted agent in first-line treatment of advanced pancreatic cancer designed on survival as primary outcome were selected. Search was done through Medline and the registry of the NIH. Keywords used for searching were ‘pancreas’, ‘pancreatic’, ‘gemcitabine’. Study quality was assessed with MERGE criteria. Findings were depicted in classical Forest plots. Publication bias was evaluated by the construction of funnel plot. Results: Nine studies met the meta-analysis inclusion criteria including 4564 patients. The target therapies were: erlotinib, cetuximab, rigosertib, elpamotide, bevacizumab, aflibercept, axitinib, masitinib and ganitumab. There was no statistically significant heterogeneity among the nine trials (p = 0.77). The hazard ratio (HR) of the pooled analysis was 0.998 (CI 95{\%}: 0.932–1.068). Subgroup meta-analysis was also performed in anti-EGFR and anti-angiogenesis trials: the pooled HR were 0.94 (CI 95{\%}: 0.705–1.175) and 1.055 (CI 95{\%}: 0.913–1.197), respectively. Conclusions: The present meta-analysis does not show significant improvements in survival for targeted drugs in advanced pancreatic cancer. The possible reason of these results could be linked to the biology of pancreatic cancer as well as to the absence of predictive factors.",
author = "Alessandro Ottaiano and Monica Capozzi and {De Divitiis}, Chiara and {De Stefano}, Alfonso and Gerardo Botti and Antonio Avallone and Salvatore Tafuto",
year = "2017",
month = "3",
day = "4",
doi = "10.1080/0284186X.2017.1288922",
language = "English",
volume = "56",
pages = "377--383",
journal = "Acta Oncologica",
issn = "0284-186X",
publisher = "Informa Healthcare",
number = "3",

}

TY - JOUR

T1 - Gemcitabine mono-therapy versus gemcitabine plus targeted therapy in advanced pancreatic cancer

T2 - a meta-analysis of randomized phase III trials

AU - Ottaiano, Alessandro

AU - Capozzi, Monica

AU - De Divitiis, Chiara

AU - De Stefano, Alfonso

AU - Botti, Gerardo

AU - Avallone, Antonio

AU - Tafuto, Salvatore

PY - 2017/3/4

Y1 - 2017/3/4

N2 - Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results. We performed a meta-analysis in order to quantify the effect size on survival of adding targeted therapy to single agent gemcitabine. Methods: Randomized phase III trials comparing gemcitabine mono-therapy versus gemcitabine plus a targeted agent in first-line treatment of advanced pancreatic cancer designed on survival as primary outcome were selected. Search was done through Medline and the registry of the NIH. Keywords used for searching were ‘pancreas’, ‘pancreatic’, ‘gemcitabine’. Study quality was assessed with MERGE criteria. Findings were depicted in classical Forest plots. Publication bias was evaluated by the construction of funnel plot. Results: Nine studies met the meta-analysis inclusion criteria including 4564 patients. The target therapies were: erlotinib, cetuximab, rigosertib, elpamotide, bevacizumab, aflibercept, axitinib, masitinib and ganitumab. There was no statistically significant heterogeneity among the nine trials (p = 0.77). The hazard ratio (HR) of the pooled analysis was 0.998 (CI 95%: 0.932–1.068). Subgroup meta-analysis was also performed in anti-EGFR and anti-angiogenesis trials: the pooled HR were 0.94 (CI 95%: 0.705–1.175) and 1.055 (CI 95%: 0.913–1.197), respectively. Conclusions: The present meta-analysis does not show significant improvements in survival for targeted drugs in advanced pancreatic cancer. The possible reason of these results could be linked to the biology of pancreatic cancer as well as to the absence of predictive factors.

AB - Background: Prognosis of advanced pancreatic cancer is dismal and the novel targeted therapies, albeit successfully used to treat many advanced tumors, have shown modest results. We performed a meta-analysis in order to quantify the effect size on survival of adding targeted therapy to single agent gemcitabine. Methods: Randomized phase III trials comparing gemcitabine mono-therapy versus gemcitabine plus a targeted agent in first-line treatment of advanced pancreatic cancer designed on survival as primary outcome were selected. Search was done through Medline and the registry of the NIH. Keywords used for searching were ‘pancreas’, ‘pancreatic’, ‘gemcitabine’. Study quality was assessed with MERGE criteria. Findings were depicted in classical Forest plots. Publication bias was evaluated by the construction of funnel plot. Results: Nine studies met the meta-analysis inclusion criteria including 4564 patients. The target therapies were: erlotinib, cetuximab, rigosertib, elpamotide, bevacizumab, aflibercept, axitinib, masitinib and ganitumab. There was no statistically significant heterogeneity among the nine trials (p = 0.77). The hazard ratio (HR) of the pooled analysis was 0.998 (CI 95%: 0.932–1.068). Subgroup meta-analysis was also performed in anti-EGFR and anti-angiogenesis trials: the pooled HR were 0.94 (CI 95%: 0.705–1.175) and 1.055 (CI 95%: 0.913–1.197), respectively. Conclusions: The present meta-analysis does not show significant improvements in survival for targeted drugs in advanced pancreatic cancer. The possible reason of these results could be linked to the biology of pancreatic cancer as well as to the absence of predictive factors.

UR - http://www.scopus.com/inward/record.url?scp=85014534885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014534885&partnerID=8YFLogxK

U2 - 10.1080/0284186X.2017.1288922

DO - 10.1080/0284186X.2017.1288922

M3 - Review article

C2 - 28256961

AN - SCOPUS:85014534885

VL - 56

SP - 377

EP - 383

JO - Acta Oncologica

JF - Acta Oncologica

SN - 0284-186X

IS - 3

ER -